In recent years, DUB inhibitors have emerged as a promising class of cancer therapeutics, with several studies demonstrating the potential of these inhibitors to suppress tumor growth by modulating DUB activity [22, 23], while their potential anti-tumor effects in HCC have been relatively underexplored. Here, ZUP1 is linked to cancer.